Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Sight Sciences, Inc., a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye conditions, ...
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma...
Sight Sciences, Inc., a growth-stage ophthalmic medical device company, today announced further favorable results of a trial evaluating a single...
Sight Sciences, Inc., a growth-stage ophthalmic medical device company, today announced positive 6-month interim safety and efficacy results from a...
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma...
Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that it has received Health Canada...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support...
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases ...
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval...
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed a $7 million Series B round...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.